Health AI Central
Share:
Peer-Reviewed Publication
Subst Use Misuse2026;1-12.July 19, 2026Journal Article

Sleep Disturbance in Opioid Use Disorder: Systematic Review of Insomnia Prevalence and Sedative-Hypnotic Utilization.

Farid Chekani1, Yifei Lu1, Astha Jain2, Sugandh Sharma3
1Merck & Co., Inc, North Wales, Pennsylvania, USA.
2Parexel International, Mohali, India.
3Parexel International, Chandigarh, India.
PubMed DOI

Abstract

BACKGROUND: Opioid use disorder (OUD) is a chronic condition affecting approximately 60 million individuals worldwide. Sleep disturbances, particularly insomnia, are highly prevalent in OUD and may worsen psychiatric symptoms, reduce treatment adherence, and increase relapse risk. However, insomnia remains underrecognized and the pharmacological treatment options for insomnia may not be optimal in…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.